Publications by authors named "A Campomori"
Article Synopsis
- The study evaluated the safety and effectiveness of rituximab biosimilars compared to the original rituximab (Mabthera) in 800 patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia across 13 centers in Italy.
- Out of 505 newly diagnosed patients analyzed, 16.8% experienced adverse drug reactions (ADRs), mostly during the first and second infusions, with the common reactions being general disorders and administration site conditions.
- The results indicate that rituximab biosimilars are clinically safe and switching between different biosimilars does not increase adverse events, potentially encouraging wider use and lowering healthcare costs.
Background: sepiapterine reductase deficiency (SRD) is a rare levodopa (L-dopa)-responsive disorder treated with a combination therapy of controlled-release L-dopa and carbidopa. The currently available formulation of controlled-release carbidopa/L-dopa does not entirely meet the requirements for the long-term therapy in pediatric patients. In fact, administration of a manufactured tablet at a dose intended for adults necessitates its adjustment to the child's needs, as the splitting of the tablet into smaller portions or its dilution in water.
View Article and Find Full Text PDFThe initial step for the differential diagnosis of hypoglycemia is to determine whether it is hyperinsulinemic or non hyperinsulinemic. Existing literature discusses drug-related hypoglycemia, but it misses a focus on drug-induced hyperinsulinemic hypoglycemia (DHH). Here we reviewed the association existing between drugs and hyperinsulinemic hypoglycemia.
View Article and Find Full Text PDFMultimorbidity and polypharmacy are emerging health priorities and the care of persons with these conditions is complex and challenging. The aim of the present guidelines is to develop recommendations for the clinical management of persons with multimorbidity and/or polypharmacy and to provide evidence-based guidance to improve their quality of care. The recommendations have been produced in keeping with the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
View Article and Find Full Text PDFIntroduction: ONCO-TreC platform consists of a mobile application delivered to patients as electronic diary and a web-based dashboard managed by healthcare professionals. We aim to compare the effectiveness of ONCO-TreC electronic diary with a standard paper diary, in improving adherence to oral cancer therapy in patients with solid and haematological tumours.
Methods And Analysis: This is an open label, superiority, randomised controlled trial conducted in two Italian oncology units.